[Performance Forecast Overview](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) The company forecasts a net loss of 7 million to 9.5 million yuan for H1 2025, a significant year-over-year decline H1 2025 Performance Forecast vs. Prior Year Period | Metric | H1 2025 Estimated | Prior Year Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss 7 million - 9.5 million yuan | Profit 14.0266 million yuan | ↓ 149.91% - 167.73% | | Net Profit After Non-Recurring Items | Loss 11.6594 million - 14.1594 million yuan | Profit 2.3089 million yuan | ↓ 604.98% - 713.25% | | Basic Earnings Per Share | Loss 0.008 - 0.011 yuan/share | Profit 0.0166 yuan/share | - | [Analysis of Performance Change Reasons](index=1&type=section&id=Item%203.%20Explanation%20of%20Performance%20Change%20Reasons) Loss attributed to lower medical engineering revenue, reduced export medical consumables profit, and a sharp decline in non-recurring income - Revenue recognized from completed medical professional engineering projects decreased by **72%** compared to the prior year period[4](index=4&type=chunk) - Sales volume and profit margins of export medical consumable products further declined[4](index=4&type=chunk) - Non-operating income from government subsidies and write-offs of receivables decreased by approximately **90%** compared to the prior year period[4](index=4&type=chunk) [Important Statement and Risk Warning](index=1&type=section&id=Item%202.%20Communication%20with%20Accounting%20Firm) This performance forecast is a preliminary, unaudited estimate; final data in 2025 semi-annual report, investors urged to note risks - The financial data related to this performance forecast has not been pre-audited by a certified public accountant[3](index=3&type=chunk) - This performance forecast is a preliminary estimate by the company's finance department; final data will be based on the '2025 Semi-Annual Report'[5](index=5&type=chunk) - The company advises investors to be aware of investment risks and to rely on information published in designated media (e.g., China Securities Journal, Securities Times, and Juchao Information Network)[6](index=6&type=chunk)

股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少621户，户均持股市值35.28万 元，户均持股数量2.76万股。 深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 7月14日，尚荣医疗今日收盘3.87元，下跌2.27%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到146.32倍，总市值32.72亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.90倍，行业中值37.22倍，尚荣医疗排 名第111位。 最新一期业绩显示，2025年一季报，公司实现营业收入2. ...

Group 1 - The company expects a net profit to be negative for the period from January 1, 2025, to June 30, 2025 [2] - The revenue from completed medical engineering projects has decreased by 72% compared to the same period last year, leading to significant losses [3] - Sales and profit margins of exported medical consumables have further declined, contributing to the overall financial downturn [3] Group 2 - Government subsidies and the write-off of receivables have resulted in a decrease of approximately 90% in non-operating income compared to the previous year [3] - The financial data for the first half of 2025 is based on preliminary estimates by the company's finance department and has not been audited [4] - The company will disclose detailed financial data in the "2025 Semi-Annual Report" and emphasizes the importance of timely information disclosure [4]

Group 1 - Yuntian Lifa plans to issue H-shares and list on the Hong Kong Stock Exchange [3] - Aerospace Electromechanical's wholly-owned subsidiary intends to transfer 70% equity of Eschong Korea [4] - Three Gorges Water Conservancy plans to publicly transfer 41.0071% equity of Chongqing Tiantai Energy Group [5] Group 2 - Galaxy Microelectronics intends to invest 310 million yuan in the construction of a high-end integrated circuit device industrialization base [6] - Wanye Enterprises' wholly-owned subsidiary plans to invest 299 million yuan to establish a private equity investment fund [7] - Dailor New Materials will invest 45 million yuan to establish a holding subsidiary [8] Group 3 - Huaxi Securities expects a net profit increase of 1025.19% to 1353.9% year-on-year for the first half of 2025 [10][11] - Guolian Minsheng anticipates a net profit increase of approximately 1183% year-on-year for the first half of 2025 [12] - Gaode Infrared expects a net profit increase of 734.73% to 957.33% year-on-year for the first half of 2025 [13] Group 4 - Tianchen Co. expects a net profit increase of 640% to 786% year-on-year for the first half of 2025 [14] - Shenkai Co. anticipates a net profit increase of 183% to 278% year-on-year for the first half of 2025 [15] - Taishan Petroleum expects a net profit increase of 123% to 173% year-on-year for the first half of 2025 [16] Group 5 - Ruikeda expects a net profit increase of 132.44% to 163.22% year-on-year for the first half of 2025 [17] - Jinkong Electric anticipates a net profit of 120 million to 150 million yuan, turning from loss to profit [18] - Ankai Bus expects a net profit increase of 106.67% to 189.34% year-on-year for the first half of 2025 [19] Group 6 - Yara International expects a net profit increase of 170% to 244% year-on-year for the first half of 2025 [20] - Zhongshun Jierou anticipates a net profit increase of 59.85% to 82.68% year-on-year for the first half of 2025 [21] - Guoan Co. expects a loss of 25.9 million to 36.7 million yuan for the first half of 2025 [22] Group 7 - Huamei Holdings expects a loss of 46.5 million to 60 million yuan for the first half of 2025 [23] - AOC Technology anticipates a loss of 450 million to 490 million yuan for the first half of 2025 [24] - Shangrong Medical expects a loss of 7 million to 9.5 million yuan for the first half of 2025 [25] Group 8 - Hangang Co. expects a net loss of approximately 111 million yuan for the first half of 2025 [26] - Baili Electric's shareholder plans to reduce its stake by no more than 2% [27] - Dream Lily's major shareholder plans to reduce its stake by no more than 0.5% [28]

[Shangrong Medical 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Shenzhen%20Shangrong%20Medical%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) This report provides the preliminary performance forecast for Shenzhen Shangrong Medical Co., Ltd. for the first half of 2025, indicating a significant shift from profit to loss [Performance Forecast](index=1&type=section&id=I.%20Estimated%20Performance%20for%20the%20Current%20Period) The company anticipates a shift from profit to loss in the first half of 2025, with net profit attributable to shareholders projected to be a loss of 7.0 million to 9.5 million yuan, representing a significant year-over-year decline of 135.65% to 167.73% compared to the prior year's profit of 14.0266 million yuan, while net profit after deducting non-recurring gains and losses is expected to decline even more sharply by 518.36% to 713.25% 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period (2025.01.01 - 2025.06.30) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Loss: 7.0 million — 9.5 million yuan | Profit: 14.0266 million yuan | | Year-over-Year Change | Decrease: 135.65% — 167.73% | - | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Loss: 9.6594 million — 14.1594 million yuan | Profit: 2.3089 million yuan | | Year-over-Year Change | Decrease: 518.36% — 713.25% | - | | **Basic Earnings Per Share** | Loss: 0.006 — 0.011 yuan/share | Profit: 0.0166 yuan/share | [Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company explicitly states that the financial data in this performance forecast has not been pre-audited by a certified public accountant, and its accuracy is subject to uncertainty - The financial data related to this performance forecast has not been pre-audited by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) The company attributes the shift from profit to loss primarily to three negative factors: a significant decline in core medical professional engineering revenue, a simultaneous decrease in both volume and price for export medical consumables, and a sharp reduction in non-operating income such as government subsidies - The primary reasons for the company's loss include[5](index=5&type=chunk) - Medical professional engineering revenue: Revenue completed and recognized in the current reporting period decreased by **72%** compared to the prior year period[5](index=5&type=chunk) - Export business: Sales volume and profit margins of medical consumable products further declined[5](index=5&type=chunk) - Non-operating income: Income from government subsidies and write-offs of receivables decreased by approximately **90%** compared to the prior year period[5](index=5&type=chunk) [Other Relevant Information](index=1&type=section&id=IV.%20Other%20Relevant%20Information) The company emphasizes that this performance forecast is a preliminary estimate by the finance department, with final accurate financial data to be disclosed in the official "2025 Semi-Annual Report," and advises investors to be aware of investment risks and rely on information published by the company in designated media - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an auditing firm[6](index=6&type=chunk) - The company reminds investors to rely on information published in designated media such as "China Securities Journal," "Securities Times," and Juchao Information Network, and to be aware of investment risks[7](index=7&type=chunk)

Core Viewpoint - Shenzhen Shangrong Medical Co., Ltd. announced a cash dividend distribution plan for the fiscal year 2024, with a total cash dividend of 6,755,714.22 yuan (including tax), distributing 0.08 yuan per 10 shares to shareholders [1][2][3]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 0.08 yuan per 10 shares, based on a total share count of 844,464,278 shares after excluding 1,030,300 shares held in the repurchase account [1][2][3]. - The total cash dividend amount is expected to be 6,755,714.22 yuan (including tax) [1][2]. Share Count and Adjustments - The total share count remains unchanged post-distribution, but the cash dividend per share will decrease due to the exclusion of repurchased shares [2][3]. - The calculation for the ex-dividend price will be based on the total share count, including repurchased shares, resulting in an adjusted price of approximately 0.079902 yuan per share [2][3][6]. Key Dates - The record date for the dividend distribution is set for July 17, 2025, and the ex-dividend date is July 18, 2025 [3][4]. Dividend Recipients - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [4][5]. Payment Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies or other custodial institutions [6].

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-036 深圳市尚荣医疗股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管 指引第9号——回购股份》等相关规定，上市公司回购专用账户中的股份不享有 利润分配等权利。深圳市尚荣医疗股份有限公司（以下简称"公司"或"本公司"） 通过回购专用证券账户持有的本公司股份1,030,300 股，不参与本次权益分派。 因此，本次权益分派以公司现有总股本845,494,578股剔除回购专用证券账户持有 的1,030,300股后共计844,464,278股为基数，向全体股东每10股派发现金红利0.08 元（含税），预计派发现金股利6,755,714.22元(含税)。本年度不送红股，不以 资本公积转增股本。 2、鉴于公司回购股份不享有利润分配的权利，根据股票市值不变原则，实 施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例将减小。 本次权益分派实施后计算除权除息价格时，按公司总股本（ ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Shangrong Medical, which has a current PE ratio of 150.86, significantly higher than the industry average of 51.42 [1][2] - As of July 7, Shangrong Medical's stock closed at 3.99 yuan, marking a 2.57% increase, with a total market capitalization of 3.374 billion yuan [1] - The company has seen a net inflow of 10.55 million yuan in principal funds on July 7, with a total inflow of 9.69 million yuan over the past five days [1] Group 2 - Shangrong Medical reported a revenue of 280 million yuan for Q1 2025, reflecting a year-on-year increase of 30% [2] - The net profit for the same period was 13.96 million yuan, showing a year-on-year growth of 0.58%, with a sales gross margin of 15.27% [2] - The company is recognized as a national high-tech enterprise and has accumulated over 180 patents, which contribute to its ongoing development [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a significant increase in stock price and a high PE ratio compared to industry averages [1][2] - As of June 23, Shangrong Medical's stock closed at 3.67 yuan, up 3.67%, with a rolling PE ratio of 138.76 times and a total market value of 3.103 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 48.89 times and a median of 35.79 times, placing Shangrong Medical at the 111th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Shangrong Medical reported an operating income of 280 million yuan, a year-on-year increase of 30%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The company's sales gross margin stands at 15.27% [2] - Shangrong Medical is recognized as a national high-tech enterprise and has received numerous awards and honors, including over 180 patents, which contribute to its ongoing development [1]

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.56倍，行业中值36.18倍，尚荣医疗排 名第111位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13尚荣医疗141.78142.291.2031.71亿行业平均 49.5647.474.64106.50亿行业中值36.1837.862.4148.50亿1英科医疗9.3810.120.83148.24亿2九安医疗 10.1310.250.80171.03亿3新华医疗14.3913.331.1792.22亿4振德医疗14.5813.740.9352.92亿5康德莱 15.0415.051.2532.41亿6奥美医疗15.0914.791.5554.52亿7山东药玻15.1115.161.74142.94亿8维力医疗 15.9616.591.8736.40亿9九强生物15.9814.861.9679.13亿10奥泰生物16.4017.291.3252.31亿11安杰思 17.4017.602.1051.64亿12三鑫医疗18.4618.473.0442.00亿 股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少62 ...